Janus Henderson Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $83.5M | Sell |
|
|||||
|
2025
Q2 | $97.5M | Sell |
|
|||||
|
2025
Q1 | $88.7M | Sell |
|
|||||
|
2024
Q4 | $108M | Buy |
|
|||||
|
2024
Q3 | $91.3M | Sell |
|
|||||
|
2024
Q2 | $134M | Sell |
|
|||||
|
2024
Q1 | $190M | Sell |
|
|||||
|
2023
Q4 | $204M | Sell |
|
|||||
|
2023
Q3 | $193M | Sell |
|
|||||
|
2023
Q2 | $180M | Sell |
|
|||||
|
2023
Q1 | $202M | Sell |
|
|||||
|
2022
Q4 | $289M | Sell |
|
|||||
|
2022
Q3 | $1.05B | Buy |
|
|||||
|
2022
Q2 | $508M | Sell |
|
|||||
|
2022
Q1 | $592M | Sell |
|
|||||
|
2021
Q4 | $634M | Sell |
|
|||||
|
2021
Q3 | $862M | Buy |
|
|||||
|
2021
Q2 | $871M | Sell |
|
|||||
|
2021
Q1 | $898M | Buy |
|
|||||
|
2020
Q4 | $878M | Buy |
|
|||||
|
2020
Q3 | $630M | Buy |
|
|||||
|
2020
Q2 | $792M | Sell |
|
|||||
|
2020
Q1 | $660M | Buy |
|
|||||
|
2019
Q4 | $793M | Sell |
|
|||||
|
2019
Q3 | $766M | Sell |
|
|||||
|
2019
Q2 | $790M | Buy |
|
|||||
|
2019
Q1 | $776M | Buy |
|
|||||
|
2018
Q4 | $629M | Buy |
|
|||||
|
2018
Q3 | $881M | Sell |
|
|||||
|
2018
Q2 | $728M | Sell |
|
|||||
|
2018
Q1 | $619M | Buy |
|
|||||
|
2017
Q4 | $448M | Buy |
|
|||||
|
2017
Q3 | $338M | Buy |
|
|||||
|
2017
Q2 | $247M | Buy |
|